Who are Relugolix Combination Tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lupron, Micronor, LHRHa, GnRH agonist/antagonist, Cetrorelix and Leuprolide, Half-Dose Depot Triptorelin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/relugolix-combination-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Relugolix Combination Tablet — Competitive Intelligence Brief

Relugolix Combination Tablet (Relugolix Combination Tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH receptor antagonist. Area: Oncology.

phase 3 GnRH receptor antagonist GnRH receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Relugolix Combination Tablet (Relugolix Combination Tablet) — Sumitomo Pharma Switzerland GmbH. Relugolix combination tablet works by inhibiting gonadotropin-releasing hormone (GnRH) receptors, leading to a decrease in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) production, which in turn reduces testosterone levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Relugolix Combination Tablet TARGET	Relugolix Combination Tablet	Sumitomo Pharma Switzerland GmbH	phase 3	GnRH receptor antagonist	GnRH receptor
Lupron	leuprorelin	Accord Healthcare S.L.U.	marketed	Gonadotropin Releasing Hormone Receptor Agonist	GnRH receptors	1985-01-01
Micronor	norethisterone	Johnson & Johnson	marketed	Progestin	GnRH receptors	1962-01-01
LHRHa	LHRHa	Imperial College London	marketed	LHRH agonist	LHRH receptor (GnRH receptor)
GnRH agonist/antagonist	GnRH agonist/antagonist	Memorial Sloan Kettering Cancer Center	marketed	GnRH agonist/antagonist	GnRH receptor
Cetrorelix and Leuprolide	Cetrorelix and Leuprolide	Instituto Valenciano de Infertilidad, IVI VALENCIA	marketed	GnRH antagonist and GnRH agonist combination	GnRH receptor
Half-Dose Depot Triptorelin	Half-Dose Depot Triptorelin	Tehran University of Medical Sciences	marketed	GnRH agonist	GnRH receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-22 — Lupron · 9617303 · US
2031-02-05 — Lupron · 8921326 · US

Sponsor landscape (GnRH receptor antagonist class)

Sumitomo Pharma Switzerland GmbH · 1 drug in this class
University of Michigan · 1 drug in this class
VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Relugolix Combination Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/relugolix-combination-tablet. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab